The Phase 3 AFFIRM-AL clinical trial was a global, double-blind, placebo-controlled, time-to-event clinical trial that enrolled 207 newly diagnosed, treatment naïve patients with Mayo Stage IV AL ...

Belite Bio, Inc. announced that the independent Data Safety Monitoring Board (DSMB) recommended the continuation of the Phase 3 DRAGON trial for Tinlarebant, an experimental treatment for ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...

In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled participants with myasthenia gravis who had anti–acetylcholine receptor antibodies or anti–muscle-specific ...